Amgen, Inc. (NASDAQ:AMGN) will unveil its latest earnings on Thursday, January 26, 2012. The average estimate of analysts is for net income of $1.24 per share, a rise of 7.8% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.20. Between one and three months ago, the average estimate moved up. It has dropped from $1.25 during the last month. For the year, analysts are projecting profit of $5.29 per share, a rise of 3.3% from last year.

Last quarter, the company beat estimates by 12 cents, coming in at net income of $1.38 a share versus the estimate of profit of $1.26 a share. It marked the fourth straight quarter of beating estimates. Analysts are projecting a rise of 2.1% in revenue from the year-earlier quarter to $3.92 billion.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Biogen Idec Inc. (NASDAQ:BIIB), GlaxoSmithKline plc (NYSE:GSK), Affymax, Inc. (NASDAQ:AFFY), Genzyme Corporation (NASDAQ:GENZ), Roche Holding Ltd. (RHHBY), Novartis AG (NYSE:NVS), 3SBio Inc. (NASDAQ:SSRX), and NPS Pharmaceuticals, Inc. (NASDAQ:NPSP).

Bristol-Myers Squibb Co. (NYSE:BMY) will unveil its latest earnings on Thursday, January 26, 2012. The average estimate of analysts is for profit of 55 cents per share, a rise of 17% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 56 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 55 cents during the last month. For the year, analysts are projecting net income of $2.30 per share, a rise of 6.5% from last year.

Last quarter, the company reported profit of 61 cents per share versus a mean estimate of net income of. The company has beaten estimates for the past three quarters. Analysts are projecting a rise of 7.6% in revenue from the year-earlier quarter to $5.5 billion.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Eli Lilly & Co. (NYSE:LLY), Sanofi-Aventis SA (NYSE:SNY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline plc (NYSE:GSK), and AstraZeneca plc (NYSE:AZN).

ResMed, Inc. (NYSE:RMD) will unveil its latest earnings on Thursday, January 26, 2012. The average estimate of analysts is for profit of 38 cents per share, a rise of 2.7% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. Analysts are projecting profit to rise by 5.5% versus last year to $1.54.

Last quarter, the company fell short of estimates by 3 cents, coming in at net income of 33 cents per share against a mean estimate of profit of 35 cents. The company topped expectations in the fourth quarter of the last fiscal year. Analysts are projecting a rise of 11% in revenue from the year-earlier quarter to $339.6 million.

Competitors to Watch: Allied Healthcare Product (NASDAQ:AHPI), Masimo Corporation (NASDAQ:MASI), Electromed, Inc. (NASDAQ:ELMD), Medtronic, Inc. (NYSE:MDT), Dynatronics Corporation (NASDAQ:DYNT), Thermo Fisher Scientific Inc. (NYSE:TMO), Covidien plc (NYSE:COV), Dehaier Medical Systems Ltd (NASDAQ:DHRM), and CareFusion Corporation (NYSE:CFN).

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!